Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Lung cancer gene therapy aims to selectively target tumors using therapeutic genes.
• A previously designed TTS promoter was intended for lung cancer cell targeting.
• Further characterization of the TTS promoter's specificity across lung cancer subtypes was needed.

Purpose of the Study:

• To characterize the specificity of the TTS promoter in four lung cancer cell types.
• To evaluate the efficacy of a TTS promoter-driven proapoptotic gene (Bax) system in pulmonary adenocarcinoma.
• To investigate drug-controllable gene therapy for gefitinib-resistant pulmonary adenocarcinoma.

Main Methods:

• Testing TTS promoter activity in squamous cell lung carcinoma, pulmonary adenocarcinoma, small-cell lung carcinoma, and large-cell lung carcinoma cells.
• Inserting the proapoptotic gene Bcl-2-associated X protein (Bax) into the TTS promoter (TTS/Bax).
• Assessing BAX expression and cell death induction in various lung cancer cells, including gefitinib-resistant lines, and evaluating dexamethasone's suppressive effect.

Main Results:

• The TTS promoter demonstrated high activity exclusively in pulmonary adenocarcinoma cells.
• The TTS/Bax system selectively induced BAX expression and cell death in pulmonary adenocarcinoma, including gefitinib-resistant cells.
• Dexamethasone treatment suppressed BAX expression and cell death via negative glucocorticoid elements in the TTS promoter.

Conclusions:

• The TTS promoter exhibits specific targeting for pulmonary adenocarcinoma, likely due to thyroid transcription factor 1-associating cofactors.
• The TTS/Bax system represents a targeted gene therapy approach for pulmonary adenocarcinoma, effective even in drug-resistant cases.
• A drug-controllable TTS/Bax system for pulmonary adenocarcinoma has been developed, offering a new therapeutic strategy.